Cagrilintide Guide — What It Is, How It Works & What the Research Shows

What it is

Cagrilintide is a lab-made version of amylin, a hormone your pancreas releases alongside insulin after eating. Natural amylin breaks down within minutes, so scientists re-engineered it into a stable, long-acting molecule that can be injected under the skin just once a week.

It was developed by Novo Nordisk (the maker of Ozempic and Wegovy) and has real human clinical-trial data behind it. Its highest-profile use is in CagriSema, a fixed-dose combination pairing cagrilintide with the GLP-1 drug semaglutide. Novo Nordisk has filed CagriSema for FDA approval, but neither CagriSema nor standalone cagrilintide is FDA-approved as of mid-2026.

On the grey market, cagrilintide is sold as a lyophilized (freeze-dried) powder labeled 'for laboratory research use only.' That version is unapproved and unregulated — it is not the pharmaceutical product being reviewed by regulators.

How it works

Amylin signals fullness. Acting mainly through amylin receptors in the brainstem's dorsal vagal complex, it slows how fast the stomach empties, reduces appetite, and helps you feel satisfied with less food. Cagrilintide mimics this satiety signal but lasts far longer than the natural hormone, giving steady once-weekly appetite suppression.

This is why it is paired with semaglutide. Amylin and GLP-1 are separate but complementary appetite pathways, so combining them appears to add up to more appetite reduction than either alone — a 'two brakes' approach to hunger. In plain terms, cagrilintide handles the amylin side of satiety while semaglutide works the GLP-1 side, and together they push food intake down further.

What people research it for

Meaningful weight loss in combination (CagriSema)

Human studies

In the Phase 3 REDEFINE 1 trial (3,417 adults without diabetes), CagriSema produced a 22.7% mean weight reduction at 68 weeks, and 91.9% of participants lost at least 5% of body weight.

Works as a standalone amylin analog

Human studies

In a Phase 2 dose-finding trial, cagrilintide monotherapy (2.4 mg) drove roughly 10-11% weight loss at 26 weeks, more than once-daily liraglutide and far above placebo.

Metabolic improvements

Human studies

CagriSema studies reported better blood pressure, waist circumference, lipids, and blood sugar; in REDEFINE 1 a large share of prediabetic participants returned to normal blood sugar.

Convenient once-weekly dosing

Human studies

Its long-acting design allows once-weekly subcutaneous injection rather than daily dosing, which historically improves adherence.

What the research actually shows

Cagrilintide has a genuine clinical-trial record. A Phase 2 monotherapy trial (Lau et al., The Lancet, 2021) established meaningful weight loss and acceptable tolerability, and an early Phase 1b study showed cagrilintide plus semaglutide added to the weight loss seen with semaglutide alone.

The headline data come from Novo Nordisk's Phase 3 REDEFINE program for CagriSema. REDEFINE 1 (adults with obesity, no diabetes) showed 22.7% mean weight loss at 68 weeks, published in the New England Journal of Medicine. REDEFINE 2 (adults with type 2 diabetes) showed a smaller ~13.7% reduction — typical of the blunted weight response seen in diabetes.

Honest limits: REDEFINE 1's 22.7% missed Novo Nordisk's own ~25% target and disappointed investors, and much of the strong data reflects the combination, not cagrilintide alone. Long-term safety, durability after stopping, and standalone value are still being studied, and the FDA has not approved either product yet.

Research handling & storage

The research-grade product ships as a lyophilized white powder in a sealed vial and must be reconstituted with bacteriostatic or sterile water before it becomes a liquid. Sealed vials are typically stored refrigerated (about 2-8 C) and kept out of light; the freeze-dried powder is more stable than the reconstituted solution.

Once mixed, it should be refrigerated and used within a limited window (commonly a few weeks), never frozen after reconstitution, and never shaken hard. Because cagrilintide is engineered for a long half-life supporting once-weekly dosing, its effects and any side effects can linger for days — relevant context for how the pharmaceutical version is designed, not dosing guidance for personal use.

Safety & cautions

The most common side effects in trials are gastrointestinal — nausea, vomiting, constipation, and diarrhea — the same profile seen with GLP-1 drugs and generally worst when doses are increased. In CagriSema trials these were the leading adverse events, and slow dose escalation is used to reduce them.

Critically, cagrilintide is investigational and not FDA-approved. Grey-market 'research only' powder is unregulated, may vary in purity or dose, is not intended for human use, and carries risks including contamination and inaccurate labeling. This guide is educational and not medical advice; only a licensed clinician can weigh appropriate use of any approved therapy.

💰

PRICE ALERTS

Track Cagrilintide prices

Get an alert when a trusted, tested vendor drops the price. Free.

Frequently asked questions

Is cagrilintide FDA approved?

No. As of mid-2026 neither standalone cagrilintide nor the CagriSema combination is FDA-approved. Novo Nordisk has submitted CagriSema for FDA review, but it remains investigational.

What is CagriSema?

CagriSema is Novo Nordisk's fixed-dose, once-weekly combination of cagrilintide (an amylin analog) and semaglutide (a GLP-1 drug). It is the first combination pairing these two hormone pathways for weight management and produced 22.7% mean weight loss in the Phase 3 REDEFINE 1 trial.

How is cagrilintide different from semaglutide?

Semaglutide is a GLP-1 receptor agonist; cagrilintide is an amylin analog. They suppress appetite through different but complementary systems, which is why combining them (CagriSema) tends to work better than either alone.

How much weight did people lose?

Cagrilintide alone gave roughly 10-11% weight loss at 26 weeks in Phase 2. The CagriSema combination reached 22.7% at 68 weeks in adults without diabetes (REDEFINE 1) and about 13.7% in adults with type 2 diabetes (REDEFINE 2).

Is the 'research only' powder the same as the drug in trials?

No. Grey-market cagrilintide labeled for laboratory research is unapproved and unregulated, with no guarantee of purity, sterility, or accurate dosing — it is not the pharmaceutical product under FDA review.

Sources

Last reviewed 2026-07-07. This guide is educational and research-focused — not medical advice. Cagrilintide products referenced on PeptidePub are sold by third parties as materials for laboratory research use only, not for human or animal consumption.

Related peptides

Or compare prices across all peptides.

Ready to compare Cagrilintide?

See prices across trusted, third-party-tested vendors, normalized per milligram.

Compare Cagrilintide prices →